
Opinion|Videos|July 18, 2024
Choosing Between Oral JAK Inhibitors in Atopic Dermatitis
Author(s)Ruth Ann Vleugels, MD, MPH, MBA
Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do you choose between different JAK inhibitors? What role do efficacy and safety data play in your selection?
- What are important considerations when choosing a JAK inhibitor in specific patient populations (e.g., older adults ≥65 yr)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
How Upadacitinib Could Expand Options for Severe Alopecia Areata, With Natasha Mesinkovska, MD, PhD
2
What Upadacitinib Could Mean for Younger Patients With Severe Alopecia Areata
3
FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis
4
Biologic Selection in Severe Asthma: Biomarkers, Comorbidities, When to Switch
5



























































